29 April 2016
Wilson Therapeutics AB (publ) (“Wilson Therapeutics” or the “Company”), HealthCap, Abingworth, MVM Life Science Partners and NeoMed (the “Main Shareholders”) have, in order to promote Wilson Therapeutics’ continued development of Decuprate® and the expansion of the Company’s operations, decided to broaden the shareholder base through a new share issue (the “Offering”).
30 March 2016
Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, today announced that it has recruited the first patient into a Phase I monotherapy trial of its lead programme, IMCgp100, for the treatment of uveal melanoma.
28 March 2016
Sonendo announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next generation of it’s GentleWave® System. This clearance provides the endodontist with the choice of using the default treatment cycles or reducing the treatment cycles as desired based on their evaluation of a tooth for root canal treatment using the GentleWave System. This most recent FDA clearance is in alignment with Sonendo’s commitment to develop products that improve clinical efficacy, treatment efficiency, and practice economy for the endodontist. Randy W. Garland, DDS, Garland Endodontics, Encinitas, CA, stated “The increase versatility of this upgrade gives the Endodontist control to treat the variety of clinical situations we are presented with.”
17 March 2016
TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal tract and eye, today announced positive Phase I study results for TOP1288, its lead compound for the treatment of ulcerative colitis (UC). TopiVert will present the Phase I study data at the 11th Congress of ECCO in Amsterdam on Friday 18 March 2016.
9 March 2016
Funding will support further Clinical Evaluation and Market Access for 4Tech TriCinch™, a breakthrough technology for Transcatheter Valve Repair (TTVR).